Immune Tolerance Network (UM1 Clinical Trial Required)
Grant Notice from a government agency.
Data as of Oct 24, 2026. Sources: SAM.gov and Grants.gov. Snapshot govcon-directory-20261024T104923Z-2151694.
This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services. Counts and totals are computed by DSE from public SAM.gov and Grants.gov notices. Text from Grants.gov may be shortened or have contact details removed. The original notice on Grants.gov is the authoritative version.
Closing in 97 days
Notice details
- Notice type
- Grant Notice
- Solicitation number
- RFA-AI-28-005
- Posted
- Oct 20, 2026
- Response deadline
- Jan 29, 2027
- Source
- Grants.gov
Description
The purpose of this notice of funding opportunity (NOFO) is to support applications to continue the Immune Tolerance Network (ITN). The primary objective of the Network is to develop tolerogenic therapies for immune-mediated disorders. The three main clinical areas of work are: 1) Allergic diseases and asthma; 2) Autoimmune diseases; and 3) Immune-mediated consequences of transplantation. The core functions of the ITN include designing, conducting, and sharing the results of clinical trials and performing integrated mechanistic studies.
Summarized from the official notice. Text from Grants.gov may be shortened or have contact details removed. The original notice on Grants.gov is the authoritative version.
Official notice
Requirements and amendments are controlled by the official notice.
DSE verdict
The DSE fit verdict for this notice is available to DSE GovCon subscribers. It is not published on this page.
See DSE GovCon plans →Get free alerts
Email alerts for notices like this one are free on DSE GovCon Intelligence.
Set up free alerts →